Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate15 out of the 16 patients had a reduction of their tumors (target lesions)79% of EVX-01’s vaccine targets...